Notes
The study was funded and supported by Novo Nordisk Scandinavia AB.
Reference
Ericsson A, et al. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLOS One : 6 Feb 2018. Available from: URL: https://doi.org/10.1371/journal.pone.0191953
Rights and permissions
About this article
Cite this article
Liraglutide add-on therapy cost effective in T2DM in Sweden. PharmacoEcon Outcomes News 797, 21 (2018). https://doi.org/10.1007/s40274-018-4730-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4730-8